Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.
In many controlled studies, CVD103-HgR has been shown to be safe and immunogenic and to offer a significant degree of protection against experimental cholera after a single dose. Its minimal excretion and limited ability to compete and survive in various ecosystems indicate that this strain presents little risk to the environment. Furthermore, the potential of CVD103-HgR to regain virulence by acquisition of the CT A or LT A gene is extremely remote even under optimal conditions. Therefore, CVD103-HgR possesses those traits desired in a live oral attenuated vaccine produced by recombinant DNA technology.
Cryz
S J
SJ
Swiss Serum and Vaccine Institute, Berne.
Kaper
J
J
Tacket
C
C
Nataro
J
J
Levine
M M
MM
D000328:Adult; D002648:Child; D002675:Child, Preschool; D022121:Cholera Vaccines / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification*; D004783:Environmental Microbiology; D005243:Feces / Q000382:microbiology; D006801:Humans; D011995:Recombination, Genetic; D012449:Safety; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification; D014734:Vibrio cholerae / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification
D022121:Cholera Vaccines; D014613:Vaccines, Attenuated